Journal
DIABETES OBESITY & METABOLISM
Volume 20, Issue 5, Pages 1302-1305Publisher
WILEY
DOI: 10.1111/dom.13202
Keywords
diabetes; glucose homeostasis; glycaemic control; insulin
Categories
Funding
- REMD Biotherapeutics, Camarillo, California
Ask authors/readers for more resources
The aim of the current study (Clinical trial reg. no. NCT02715193, clinicaltrials.gov) was to study the efficacy and safety of REMD-477, a glucagon receptor antagonist, in type 1 diabetes. This was a randomized controlled trial in which 21 patients with type 1 diabetes were enrolled. Glycaemic control and insulin use were evaluated in outpatient and inpatient settings, before and after a single 70-mg dose of REMD-477 (half-life 7-10 days) or placebo. Inpatient insulin use was 26% (95% CI, 47%, 4%) lower 1 day after dosing with REMD-477 than with placebo (P=.02). Continuous glucose monitoring during post-treatment days 6 to 12 showed that average daily glucose was 27 mg/dL lower (P<.001), percent time-in-target-range (70-180 mg/dL) was similar to 25% greater (similar to 3.5 h/d) (P=.001), and percent time-in-hyperglycaemic-range (>180 mg/dL) was similar to 40% lower (similar to 4 h/d) (P=.001) in the REMD-477 group than in the placebo group, without a difference in percent time-in-hypoglycaemic-range (<70 mg/dL). No serious adverse events were reported. Glucagon receptor antagonism decreases insulin requirements and improves glycaemic control in patients with type 1 diabetes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available